✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Jenburkt Pharmaceuticals Ltd.

JENBURPH

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹543 Cr.
P/E
16.44

Jenburkt Pharmaceuticals Ltd.

  • Jenburkt Pharma
  • Medicamen Biotech
  • Prevest Denpro

FAQs on Jenburkt Pharmaceuticals Ltd. Shareprice

Jenburkt Pharma has given better returns compared to its competitors.
Jenburkt Pharma has grown at ~22.58% over the last 4yrs while peers have grown at a median rate of 20.2%

Yes, Jenburkt Pharma is expensive.
Latest PE of Jenburkt Pharma is 16.44, while 3 year average PE is 13.73.
Also latest EV/EBITDA of Jenburkt Pharma is 12.78 while 3yr average is 9.17.

View FAQ's On Business

Growth Table

  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Balance Sheet

  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Cash Flow

  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Quarterly Results

  • Jenburkt Pharmaceuticals Ltd.
  • Medicamen Biotech
  • Prevest Denpro

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Jenburkt Pharmaceuticals Ltd. Financials

Balance sheet of Jenburkt Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Jenburkt Pharma is increasing.
Latest net debt of Jenburkt Pharma is -₹9.65 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹47.25 Crs.

Yes, profit is increasing.
The profit of Jenburkt Pharma is ₹33 Crs for TTM, ₹32.06 Crs for Mar 2025 and ₹25.98 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jenburkt Pharma latest dividend payout ratio is 24.78% and 3yr average dividend payout ratio is 25.53%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech